new sites (Steeg 2006) . Tumor cells enter the lymphatic vasculature by invading preexisting lymphatic vessels in the tumor periphery or by eliciting lymphangiogenesis via growth factor production in regional lymph node metastasis, which represents the first step of tumor dissemination for a variety of human common cancers (Sundar and Ganesan 2007; Tammela and Alitalo 2010) . Studies over the past decade have revealed a signal-transduction system for lymphatic endothelial cell proliferation, migration, and survival. This system consists of vascular endothelial growth factors (VEGF)-C and -D and their receptor vascular endothelial growth factor receptor (VEGFR)-3 (Shibuya et al. 2006; Sundar and Ganesan 2007) . Recently, a natural endogenous soluble form of VEGFR-2 (esVEGFR-2) has been described in mouse and human (Albuquerque et al. 2009 ). esVEGFR-2, the product of alternative mRNA splicing, is composed of only six of the seven extracellular immunoglobulin-like domains, and it is distinguished from the soluble VEGFR-2 (sVEGFR-2), which is produced by proteolytic shedding from the cell surface and contains the seven extracellular immunoglobulin-like domains Shibata et al. 2010 ). Both esVEGFR-2 and sVEGFR-2 can inhibit developmental and reparative lymphangiogenesis by trapping VEGF-C at a circulating level, indicating that modulation of esVEGFR-2/sVEGFR-2 might have therapeutic effects in the treatment of lymphatic vascular disorders, including tumor lymphangiogenesis (Albuquerque et al. 2009; Shibata et al. 2010) . Furthermore, circulating esVEGFR-2/sVEGFR-2 and their correlation with clinicopathological features have been described in several cancers, including gastric cancer, cervical cancer, and neuroblastoma (Kuemmel et al. 2009; Becker et al. 2010; Kikuchi et al. 2011) . However, the expression and clinical significance of esVEGFR-2 in ESCCs have not been elucidated.
In this study, quantitative RT-PCR (qRT-PCR) and immunohistochemical staining were performed to determine the expression of esVEGFR-2 in ESCC tissues. Furthermore, the clinical significance of esVEGFR-2 was also explored.
Materials and Methods

Patients and Clinical Samples
The primary tumor tissues from patients diagnosed with ESCC at Shantou Central Hospital were collected before treatment/chemotherapy. Informed consent was obtained from all subjects. The tissues used for qRT-PCR were collected between December 2007 and October 2010, and the paraffin-embedded specimens used for immunohistochemistry (IHC) were collected between February 2000 and December 2006. The clinical information of all patients is listed in Table 1 . Staging was defined according to the seventh edition of the TNM Classification of Malignant Tumors of the International Union against Cancer (UICC). This project was approved by the Ethics Committee of Shantou Central Hospital. All work was done in accordance with the Ethics Declaration of Shantou Central Hospital.
qRT-PCR
Total RNA was isolated from 90 paired primary tissues by TRIzol Reagent (Invitrogen; Carlsbad, CA), and cDNA was synthesized according to the Reverse Transcription System instructions (Promega; Madison, WI). Amplification primers were as follows:
5′-GCCTTGCTCAAGACAGGAA G-3′ (forward) and 5′-CAACTGCCTCTGCAC AATGA-3′ (reverse) 
VEGF-C:
5′-TGAACACCAGCACGAGCTAC-3′ (forward) and 5′-GCCTTGAGAGAGAGGCACT G-3′ (reverse) β-actin: 5′-CAACTGGGACGACATGGAGAAA-3′
(forward) and 5′-GATAGCAACGTACATGGCT GGG-3′ (reverse)
All primers were designed to produce fragments that spanned exon-intron boundaries and excluded amplification of genomic DNA. The primers were also designed to detect all known splice variants of the respective gene of interest. For esVEGFR-2, the reverse primer recognized the intron 13 motif, which was specific for the truncated transcript variant of this secreted form of VEGFR-2 (Albuquerque et al. 2009 ). For the normalization of the results, β-actin was used as the internal reference. qRT-PCR was performed with a Rotor-Gene 6000 (Corbett Life Science; Sydney, Australia), using SYBR PreMix Ex Taq (TaKaRa, Otsu, Japan). The amplification protocol was as follows: 30 sec preincubation at 95C followed by 45 cycles of 10 sec at 95C, 5 sec at 58C, and 15 sec at 72C. The ΔΔ Ct method was employed to analyze the data. Ct values were calculated following the manufacturer's instructions (Corbett Life Science).
Immunohistochemical Staining for esVEGFR-2
A total of 182 formalin-fixed, paraffin-embedded ESCC specimens were placed in a tissue microarray, the protocol of which was described in our previous article (Zhang et al. 2008 ). An antibody against human esVEGFR-2 was produced by Capital Bio-sciences (Beijing, China), as reported by Albuquerque et al. (2009) . To ensure the specificity of the primary antibody (Suppl. Fig. S1 ), we replaced it with PBS, preimmune rabbit serum, and blocking peptide as a negative control, as described in the protocol by Albuquerque et al. In addition, normal skin tissue was examined as a positive control. After deparaffinization and rehydration, all sections were incubated in 3% hydrogen peroxide for 10 min to block endogenous peroxidase activity. Antigen retrieval was performed by microwave oven heating (10 min) in 0.01 M sodium citrate buffer (pH 6.0). Sections were incubated with 10% normal goat serum in PBS for 15 min at room temperature to block nonspecific binding. Then, all sections were incubated at 4C overnight with rabbit polyclonal antibody against esVEGFR-2 (1:50 dilution). Next, slide immunostaining was detected by the application of the SuperPic Ture Polymer Detection kit and Liquid DAB Substrate kit (Invitrogen), counterstained with hematoxylin, and then dehydrated and mounted.
Evaluation of Immunohistochemical Staining
Evaluation of immunohistochemical staining was described in detail in our previous article (Cui et al. 2008) . Positive reactions were defined as those showing brown signals in the cell cytoplasm. Each separate tissue core was scored on the basis of the intensity and area of the positive staining. The intensity of positive staining was scored as follows: 0, negative; 1, weak staining; 2, moderate staining; and 3, strong staining. The rate of positive cells was scored on a 0 to 4 scale: 0, 0-5%; 1, 6-25%; 2, 26-50%; 3, 51-75%; and 4, >75%. If the positive staining was homogeneous, a final score was achieved by multiplication of the two scores above, producing a total range of 0 to 12. When the staining was heterogeneous, we scored it as follows: each component scored independently and summed for the results. For example, a specimen containing 25% tumor cells with moderate intensity (1 × 2 = 2), 25% tumor cells with weak intensity (1× 1 = 1), and 50% tumor cells without immunoreactivity received a final score of 2 + 1 + 0 = 3. Strong immunoreactivity of esVEGFR-2 in squamous epithelial cells of mouse and human was observed by an immunohistochemical method in a previous study (Albuquerque et al. 2009 ). In our study, predominant expression of esVEGFR-2 protein was also observed in adjacent normal esophageal squamous epithelial cells. The scores of adjacent normal esophageal epithelial tissues were 9 to 12. For statistical analysis, we divided all the samples of ESCC into two groups according to positive expression as follows: scores of 0 to 8 as low expression and scores of 9 to 12 as high expression.
Statistical Methods
Statistical analyses were performed using the statistical package SPSS version 13.0 (SPSS, Inc, an IBM Company, Chicago, IL). Using the Chi-square test, we compared high expression with low expression of esVEGFR-2 and VEGF-C mRNA in ESCC samples on the basis of clinicopathological factors, including age at diagnosis, sex, histologic type, pathological stage, and pTNM. When we obtained expected numbers of less than 5, Fisher's exact test was applied. Survival analysis of ESCC patients was performed using the log-rank test for comparison of low-expression with highexpression esVEGFR-2 immunohistochemical staining. Kaplan-Meier curves for the two groups were plotted based on overall survival. We accounted for clinical factors by univariate analysis and Cox proportional hazards models; p values of less than 0.05 were considered significant.
Results
RNA Levels of esVEGFR-2 and VEGF-C in ESCCs
Levels of esVEGFR-2 and VEGF-C mRNA were addressed by qRT-PCR. Results showed that esVEGFR-2 mRNA levels in 64.4% of ESCC tissues (58/90) were significantly lower (2 -ΔΔCt <1) than in corresponding non-neoplastic esophageal mucosa tissues (Fig. 1A) . Furthermore, we observed that esVEGFR-2 mRNA downregulation was correlated with the pTNM stages of ESCC patients. Table 2 ). In contrast, the level of VEGF-C mRNA was obviously increased in 64.4% (58/90) of cases (Fig. 2B) . No significant differences between VEGF-C mRNA level and ESCC clinicopathological features were found (Table  2) .
Protein Expression of esVEGFR-2 and Its Effect on Overall Survival
Immunohistochemical staining showed that esVEGFR-2 was distributed in the cytoplasm of cells. In normal esophagus, esVEGFR-2 protein was detected in epithelial cells from basal to superficial layers, and stronger immunoreactivity was observed in prickle and basal cell layers ( Fig.  2A) . In ESCCs, diffuse cytoplasmic staining to different degrees was observed (Fig. 2B-D) . In total, 65.9% (120/182) of ESCC cases showed esVEGFR-2 low expression (scores of 0-8), and 34.1% (62/182) exhibited high expression (scores of 9-12; Table 3 ), indicating that esVEGFR-2 protein level was inclined to be reduced. The correlations between esVEGFR-2 protein level and clinicopathological parameters were also analyzed. A significant positive association between esVEGFR-2 protein level in the cytoplasm and lymph node metastases was identified (χ 2 = 7.325, p=0.026; Table 3 ).
Kaplan-Meier survival analysis was used to address the impact of esVEGFR-2 expression on the overall survival of ESCC patients. Results showed that high esVEGFR-2 expression was associated with decreased overall survival (χ 2 = 6.366, p=0.012; Fig. 3 ). Next, we included esVEGFR-2 expression in further prognostic value analysis. In the univariate analysis, esVEGFR-2 protein accumulation in the cytoplasm was a significant prognostic indicator for ESCC patients (F = 4.955, p=0.027; Table 4 ). Multivariate analysis showed that high esVEGFR-2 expression (hazard ratio, 1.606; 95% confidence interval [CI], 1.042-2.476; p=0.032), as well as lymph node metastasis (hazard ratio, 2.651; 95% CI, 1.701-4.132; p<0.001), was a significant independent prognostic factor for poor overall survival of ESCC patients (Table 4) .
Discussion
To date, although there have been prior studies of esVEGFR-2 in diverse cancers, these studies have not been wholly focused on the relationship between esVEGFR-2 expression and prognosis of cancer patients. In the current study, we explored the expression pattern of esVEGFR-2 in ESCC, esophageal squamous cell carcinoma; esVEGFR-2, endogenous soluble vascular endothelial growth factor receptor-2; VEGF-C, vascular endothelial growth factor C. a ESCC tissue samples and showed that esVEGFR-2 was downregulated in ESCC tissues, and also showed that high expression of esVEGFR-2 protein in ESCC tissues was a significant independent prognostic factor for poor survival of patients. esVEGFR-2, a new splicing variant of VEGFR-2, could inhibit developmental and reparative lymphangiogenesis by blocking VEGF-C function. Here, we revealed that the mRNA level of esVEGFR-2 was decreased in ESCCs, whereas the mRNA level of VEGF-C was increased. Moreover, a positive correlation was found in the subsequent analysis between downregulated esVEGFR-2 mRNA expression and the pTNM stages of ESCC patients, which was characterized by lymphatic metastasis in progressed stages. This result was in accordance with the results of a previous study in neuroblastoma . It was reported that variable promoter hypermethylation of VEGFR-2, from which mRNA alternative splicing generates the esVEGFR-2 isoform (Albuquerque et al. 2009 ), influenced its expression in stomach cancer, colon cancer, and hepatocellular carcinoma (Kim et al. 2009 ). We presumed that in ESCC, methylated VEGFR-2/KDR might lead to the downregulation of esVEGFR-2 mRNA expression.
As a lymphangiogenesis inhibitor, higher esVEGFR-2 protein should inhibit tumor lymphangiogenesis and adversely affect tumor metastasis via lymphatic vessels, resulting in better survival of patients with ESCC. However, it was both interesting and puzzling that our immunohistochemical data for esVEGFR-2 protein expression contradicted this presumption. There was a positive correlation between lymph node metastasis and esVEGFR-2 protein expression detected by the immunohistochemical method. Furthermore, we also found that esVEGFR-2 protein level was inclined to be reduced, and that a lower esVEGFR-2 protein level in the cytoplasm was significantly related with a better prognosis. Multivariate analysis revealed that high esVEGFR-2 protein expression was a significant independent prognostic factor for poor cancer-specific survival of patients with ESCC. These data indicated that esVEGFR-2 might have some new functions in the progression of ESCC. The data from Lorquet et al. (2010) supported that, in addition to trapping VEGF at a circulating level, sVEGFRs could form a signaling-inactive membrane-associated complex consisting of sVEGFR/VEGF/VEGFR-2 that prevents VEGF-driven angiogenesis and/or lymphangiogenesis, and that can also bind endothelial cells through interaction with a coreceptor, which could subsequently generate a transsignaling to induce the migration of neighbor cells. Therefore, we hypothesized that, at the molecular level, a secretary dysfunction of mature esVEGFR-2 in cancer cells and/or endocytosis of mature esVEGFR-2 in the microenvironment by cancer cells could accompany the downregulation of esVEGFR-2 expression in the cells and aggravate a reduction of esVEGFR-2 in blood circulation, resulting in more free VEGF-C to activate the pathways responsible for lymphatic vessel growth. The accumulation of esVEGFR-2 in cancer cells could subsequently induce their migration and invasion by activating some signaling pathways. Further studies are under way. VEGF-C can specifically bind to VEGFR-3 and induce tyrosine autophosphorylation of VEGFR-3, indicating its role in lymphangiogenesis (Joukov et al. 1996) . VEGF-C binding to VEGFR-2 is also involved in hemangiogenesis, but its affinity is about an order of magnitude weaker than that of VEGF-A for VEGFR-2 (Kiec- Wilk et al. 2009 ). Furthermore, the VEGF-C/VEGFR-3 pathway can be blocked by esVEGFR-2 (Albuquerque et al. 2009 ). Thus, we detected VEGF-C expression in ESCC patients. This study showed that VEGF-C mRNA expression in ESCC lesions was upregulated, but we did not observe any statistically significant differences between VEGF-C mRNA level and clinicopathological features of ESCC patients. Therefore, the clinical significance of VEGF-C and the relationship between VEGF-C and esVEGFR-2 needs further explanation in ESCC patients.
In conclusion, we showed that expression of esVEGFR-2 was significantly downregulated at the mRNA and protein level in ESCC lesions in comparison with non-neoplastic esophageal mucosa. The altered expression of esVEGFR-2 was correlated with tumor progression and shorter survival of ESCC patients. To conclude, esVEGFR-2 could be used as a new independent prognostic marker for ESCC patients.
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